With EGF treatment, pAKT was significantly increased in cells harboring T790M, L858R, WT, and some of HCC-derived mutants (K757E, N808S, and P937L), as compared to without EGF treatment (Fig. 3a, b). Here, EGF is linked to hepatocellular carcinoma.